-+ 0.00%
-+ 0.00%
-+ 0.00%

NUVECTIS PHARMA ANNOUNCES THE INITIATION OF THE PHASE 1B STUDY OF NXP900 IN COMBINATION WITH OSIMERTINIB IN PATIENTS WITH NSCLC

路透·12/17/2025 12:00:03

登錄查看新聞詳情